Whitney Snider, MD, MBA, joins Memorial Sloan Kettering Cancer Center as the inaugural Managing Partner of MSK Ventures

Memorial Sloan Kettering Cancer Center (MSK) has welcomed Whitney Snider, MD, MBA, as the inaugural Managing Partner of MSK Ventures - a dedicated investment pool that will raise and direct funds to high-growth, early-stage startups created and/or nurtured by MSK faculty and staff.

MSK Ventures is designed to help translate some of MSK's most promising therapies and technologies into real-world impact. Aligned with MSK's strategic framework, MSK Ventures will accelerate investment in and development of breakthrough oncology innovations and inventions - improving patient outcomes and generating financial returns that can be reinvested into MSK's clinical and research enterprise.

As MSK Ventures Managing Partner, Dr. Snider will be instrumental in guiding faculty and staff through the process of bringing innovations to market and helping MSK intellectual property (IP) and other protected products achieve higher value and impact.

"We are very excited to welcome Dr. Snider to MSK," said Anaeze Offodile II, MD, MPH, EVP and Chief Strategy Officer of MSK. "She brings exceptional judgment, a powerful professional network, and a distinguished track record in strategic biotechnology investing. Together, these strengths will accelerate the activation and expansion of the MSK Ventures portfolio, positioning it for transformative impact. We view MSK Ventures as a pivotal lever in advancing the institution's long-term innovation and growth ambitions."

Dr. Snider brings extensive experience at the intersection of science, entrepreneurship, and investing to this role. She spent the last six years at Alexandria Venture Investments, serving as Principal and later Vice President of Life Sciences. There, she sourced and led more than $200 million in major investments for biotech, life science therapeutics, and novel platforms. Before that, Dr. Snider was a Principal at Inning One Ventures - a venture fund focused on young companies that were just getting started - where she oversaw analysis and risk mitigation for investment decisions, investment sourcing, and company formation. Notably, she co-led the formation of Ajax Therapeutics, working closely with Ross Levine, MD, MSK's Chief Scientific Officer of MSK.

Earlier in her career, Dr. Snider served as Director of Business Development at Celgene Corporation, where she worked on a landmark $1 billion immuno-oncology partnership with Juno Therapeutics to pioneer therapies in the CAR-T space. Dr. Snider earned her MD from Tufts University School of Medicine and has published translational research in hematology/oncology - collaborating with a team of researchers at Beth Israel Deaconess Medical Center to evaluate the efficacy of a new cancer vaccine. She also worked as a Consultant at Bain & Company before earning her MBA with High Distinction from Harvard Business School, where she focused on entrepreneurship and venture capital.